adamantane has been researched along with Weight Loss in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kolik, LG; Konstantinopolsky, MA | 1 |
| Al-Arouj, M; Chawla, MS; Ditommaso, S; Hassoun, AA; Hristoskova, S; Kadwa, MY; Medlej, R; Pathan, MF; Shaltout, I | 1 |
| Tibaldi, JM | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 1 |
| Bader, G; Blüher, M; Foley, JE; Schweizer, A | 1 |
| Brady, EM; Dales, J; Davies, MJ; Gray, LJ; Hanif, W; Khunti, K | 1 |
| Evans, M; Foley, JE; Schweizer, A | 1 |
| Unger, J | 1 |
| Fakhoury, WK; Lereun, C; Wright, D | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 1 |
| Barbosa, F; Bogatcheva, E; Chen, P; de los Santos, G; Einck, L; Hanrahan, C; Nacy, C; Nikonenko, B; Protopopova, M; Reddy, V | 1 |
| Hirano, T; Miyazaki, A; Mori, Y; Nagashima, M; Nohtomi, K; Terasaki, M; Watanabe, T | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
4 review(s) available for adamantane and Weight Loss
| Article | Year |
|---|---|
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Fasting; Female; Humans; Linear Models; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Holidays; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Liraglutide; Nitriles; Observational Studies as Topic; Pioglitazone; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Vildagliptin; Weight Loss | 2015 |
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss | 2010 |
2 trial(s) available for adamantane and Weight Loss
| Article | Year |
|---|---|
Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypoglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Intention to Treat Analysis; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Gain; Weight Loss | 2014 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Weight Loss | 2012 |
7 other study(ies) available for adamantane and Weight Loss
| Article | Year |
|---|---|
Comparative Assessment of the Effectiveness of Noncompetitive NMDA Receptor Antagonists Amantadine and Hemantane in Morphine Withdrawal Syndrome Model.
Topics: Adamantane; Amantadine; Animals; Gene Expression; Hyperalgesia; Injections, Intraperitoneal; Male; Morphine; Morphine Dependence; Motor Activity; Narcotic Antagonists; Rats; Receptors, N-Methyl-D-Aspartate; Substance Withdrawal Syndrome; Weight Loss | 2019 |
The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study.
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Islam; Male; Medication Adherence; Middle Aged; Nitriles; Prospective Studies; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin; Weight Loss | 2013 |
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus.
Topics: Adamantane; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Female; Humans; Linear Models; Lipids; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vildagliptin; Weight Loss | 2016 |
Choosing among the incretin agents and why it matters.
Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Identification of SQ609 as a lead compound from a library of dipiperidines.
Topics: Adamantane; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Macrophages; Mice; Mice, Inbred C3H; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Piperidines; Small Molecule Libraries; Structure-Activity Relationship; Weight Loss | 2011 |
Effects of PKF275-055, a dipeptidyl peptidase-4 inhibitor, on the development of atherosclerotic lesions in apolipoprotein E-null mice.
Topics: Adamantane; Animals; Apolipoproteins E; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dipeptidyl-Peptidase IV Inhibitors; Foam Cells; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Lipoproteins, LDL; Male; Mice; Nitriles; Plaque, Atherosclerotic; Pyrrolidines; Weight Loss | 2012 |